BGM0504
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
BrightGene Bio-Medical Technology Co · Phase 2 · Recruiting · Enrollment 200
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| The dose1 group | n/r | n/r | n/r | n/r | n/r |
| The dose2 group | n/r | n/r | n/r | n/r | n/r |
| The dose3 group | n/r | n/r | n/r | n/r | n/r |
| The dose4 group | n/r | n/r | n/r | n/r | n/r |
| Placebo group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.